Jeff Yass’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-158,135
| Closed | -$28.4M | – | 10415 |
|
|
2017
Q3 | $28.4M | Sell |
158,135
-129,041
| -45% | -$18M | 0.01% | 982 |
|
|
2017
Q2 | $29.8M | Buy |
287,176
+261,616
| +1,024% | +$21.3M | 0.01% | 879 |
|
|
2017
Q1 | $2.01M | Sell |
25,560
-96,048
| -79% | -$5.94M | ﹤0.01% | 3718 |
|
|
2016
Q4 | $5.45M | Buy |
121,608
+76,082
| +167% | +$3.73M | ﹤0.01% | 2275 |
|
|
2016
Q3 | $2.54M | Buy |
+45,526
| New | +$2.54M | ﹤0.01% | 3159 |
|
|
2016
Q2 | – | Sell |
-88,936
| Closed | -$4.37M | – | 9844 |
|
|
2016
Q1 | $4.08M | Buy |
88,936
+25,249
| +40% | +$1.22M | ﹤0.01% | 2589 |
|
|
2015
Q4 | $3.92M | Buy |
63,687
+49,108
| +337% | +$3.46M | ﹤0.01% | 2869 |
|
|
2015
Q3 | $812K | Sell |
14,579
-132,712
| -90% | -$8.35M | ﹤0.01% | 6181 |
|
|
2015
Q2 | $8.98M | Buy |
147,291
+51,931
| +54% | +$2.96M | ﹤0.01% | 2133 |
|
|
2015
Q1 | $5.5M | Buy |
95,360
+86,943
| +1,033% | +$5.83M | ﹤0.01% | 2609 |
|
|
2014
Q4 | $485K | Buy |
+8,417
| New | +$354K | ﹤0.01% | 7269 |
|
Jeff Yass's KITE Position: Q4 2017 in Review
Jeff Yass sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 158,135 shares — an estimated $28.4M sold.
Jeff Yass first reported a position in KITE in Q4 2014 and held it in 11 quarters. The position peaked at $29.8M in Q2 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Jeff Yass reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Jeff Yass sold 158,135 Kite Pharma, Inc. shares in Q4 2017, an estimated $28.4M.
- Jeff Yass first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 11 quarters.
- Jeff Yass's Kite Pharma, Inc. position peaked at $29.8M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Susquehanna International Group's 13F filing for Q4 2017, filed 14 Feb 2018.